HLA-DOB and plasma cell myeloma: HLA-DOB, a B-cell lineage, MHC-II-related molecule has been reported to have strong immunogenicity for human T-cells, one of its identified CTL epitopes HLA-DOB232–240 acts as a resilient immunotherapeutic candidate for targeting multiple myeloma (65).